TRADE NEWS: Agilent Technologies and Applied Proteomics Will Collaborate to Maximize Capabilities of Highly Multiplexed Protein

  TRADE NEWS: Agilent Technologies and Applied Proteomics Will Collaborate to
  Maximize Capabilities of Highly Multiplexed Protein Assays

Business Wire

SANTA CLARA, Calif. & SAN DIEGO -- March 7, 2013

Agilent Technologies Inc. (NYSE:A) and Applied Proteomics Inc. today agreed to
collaborate on highly multiplexed protein assays and workflow solutions for
multiple reaction monitoring through mass spectrometry. Proteins perform many
important cellular functions, are the targets of most drugs and therapies, and
are often used as biomarkers for detecting and monitoring disease.

Applied Proteomics will leverage Agilent 6490 Triple Quadrupole MS/MS, 1290
Infinity LC, RapidFire 360 MS system and Bravo liquid-handling technologies to
optimize the throughput of highly multiplexed proteomic assays. Multiple
reaction monitoring, a highly specific and sensitive mass-spectrometry
technique, can detect and quantify analytes from plasma, serum and other
biological samples. A multiplex assay can simultaneously measure multiple
analytes, such as proteins, peptides, metabolites and lipids.

“The ability to quickly and accurately measure, monitor and analyze a large
number of protein biomarkers in a single test has important applications for
understanding human diseases and developing new clinical diagnostics,” said
John E. Blume, Ph.D., chief science officer of Applied Proteomics. “Agilent’s
innovation in mass spectrometry is an important part of this collaboration as
we work together to expand the capabilities of multiplex protein assays.”

Applied Proteomics specializes in a proteomics platform solution with mass
spectrometry-based systems control and computational expertise to rapidly
collect, process and analyze proteins. Proteomics is the study of the
structure and function of proteins and how they interact within a complex
biological system.

“We are thrilled to be collaborating with Applied Proteomics, an organization
that has leading expertise in developing mass spectrometry-based methods and
instrumentation technologies for protein quantification and proteome
applications,” said Can Ozbal, director of Agilent’s RapidFire business.
“Agilent’s innovative automation, measurement and software platforms transform
complete workflow solutions from sample preparation through data acquisition,
analysis and evaluation in quantitative proteomics and biomarker validation.”

About Applied Proteomics Inc.

Applied Proteomics Inc. is advancing the application of proteomics to the
development of diagnostics, companion diagnostics, and personalized medicine
applications to power better medical decisions and care. API has developed a
proteomics platform solution to make protein-based biomarker discovery
possible as a replicable, industrial application ready to be applied to health
diagnostic problems. API’s platform combines improved instrumentation, faster
computing and extensive genome annotations with regimented standard operating
procedures, extensive quality controls, and documented processes spanning
hundreds of steps from sample collection to processing through informatics.
API is currently advancing several internal diagnostic development programs.
API is headquartered in San Diego, Calif. For more information, visit

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at


Agilent Technologies Inc.
Eric Endicott, +1-408-553-2005
Applied Proteomics
Jessica Yingling, +1-858-344-8091
Press spacebar to pause and continue. Press esc to stop.